Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression

摘要: Patients with progressive glioblastoma (GBM) have a poor prognosis. Neutrophil/lymphocyte ratio (NLR), host inflammatory marker, is prognostic in several solid tumors. The impact of either NLR, or time from first surgery for GBM to progression (TTP), patients undergoing second surgery, has not been assessed. were retrospectively reviewed. Primary outcome was overall survival (OS) and Cox proportional hazard models used assess the value baseline characteristics including TTP NLR. Univariable multivariable analysis (MVA) OS performed using accelerated failure Weibull model. Of 584 GBM, 107 (18 %) underwent between 01/04 12/11. who had longer versus those having primary alone; 20.9 9.9 months (P 4 9.7 5.9 (log rank P = 0.02). NLR retained its significance on MVA (time [TR] 1.65, 95 % confidence interval [CI] 1.15-2.35, 24 months, median 7.2, 7.0 6.3 respectively 0.6). A > prior factor later associated but after surgery.